Mira Jung

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

Positive Breast Cancer

Histone Deacetylase

Estrogen Receptor

Dna Damage Response

Top Venues

Cancer research communications

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Mira Jung, Nicole Nicholas, Scott Grindrod, Anatoly Dritschilo
Dual-targeting class I HDAC inhibitor and ATM activator, SP-1-303, preferentially inhibits estrogen receptor positive breast cancer cell growth. PloS one 19 (7) (2024)
Mira Jung, Nicole Nicholas, Scott Grindrod, Anatoly Dritschilo
Dual-targeting class I HDAC inhibitor and ATM activator, SP-1-303, preferentially inhibits estrogen receptor positive breast cancer cell growth. PloS one 19 (7) (2024)
Satish Kumar R Noonepalle, Scott Grindrod, Nima Aghdam, Xintang Li, Maria Gracia-Hernandez, Christian Zevallos-Delgado, Mira Jung, Alejandro Villagra, Anatoly Dritschilo
Radiation therapy-induced immune response enhanced by selective HDAC6 Inhibition. Molecular cancer therapeutics (2023)
Mira Jung, Keith J Kowalczyk, Ryan Hankins, Gaurav Bandi, Bhaskar Kallakury, Michael A Carrasquilla, Partha P Banerjee, Scott Grindrod, Anatoly Dritschilo
Novel Paired Normal Prostate and Prostate Cancer Model Cell Systems Derived from African American Patients. Cancer research communications 2 (12) (2022)
Mira Jung, Keith J Kowalczyk, Ryan Hankins, Gaurav Bandi, Bhaskar Kallakury, Michael A Carrasquilla, Partha P Banerjee, Scott Grindrod, Anatoly Dritschilo
Novel Paired Normal Prostate and Prostate Cancer Model Cell Systems Derived from African American Patients. Cancer research communications 2 (12) (2022)